Literature DB >> 18055323

Molecular biology of thyroid cancer initiation.

G Riesco-Eizaguirre1, P Santisteban.   

Abstract

Thyroid cancers stand out among solid tumours because many of the tumour-initiating genetic events have been identified. Mutations leading to constitutive activation of MAP kinase effectors -the tyrosine receptor kinase RET and the intracellular signalling effectors RAS and BRAF- are essential for the pathogenesis of papillary thyroid carcinoma (PTC). Similarly, there is increasing evidence demonstrating that mutations leading to activation of the phosphatidylinositol 3- kinase (PI3K)/AKT effectors -PTEN and PI3KCa- are essential for the pathogenesis of follicular thyroid carcinoma (FTC). Besides this strong relationship between the histological phenotype and the pathway predominantly activated, the nature of the genetic event seems to determine the biological behaviour of the tumour and the ultimate clinical outcome of the patient. In this review we will summarise and discuss the main genetic events related to thyroid cancer initiation, the contribution of genomics and the convenience of using a new molecular classification of thyroid cancer, complementary to the clinicopathological classification. This may help us to predict more faithfully the clinical outcome of patients with thyroid cancer and to select more appropriately candidates for targeted therapies.

Entities:  

Mesh:

Year:  2007        PMID: 18055323     DOI: 10.1007/s12094-007-0125-1

Source DB:  PubMed          Journal:  Clin Transl Oncol        ISSN: 1699-048X            Impact factor:   3.405


  78 in total

1.  Distinct pattern of ret oncogene rearrangements in morphological variants of radiation-induced and sporadic thyroid papillary carcinomas in children.

Authors:  Y E Nikiforov; J M Rowland; K E Bove; H Monforte-Munoz; J A Fagin
Journal:  Cancer Res       Date:  1997-05-01       Impact factor: 12.701

2.  CEP-701 and CEP-751 inhibit constitutively activated RET tyrosine kinase activity and block medullary thyroid carcinoma cell growth.

Authors:  Christopher J Strock; Jong-In Park; Mark Rosen; Craig Dionne; Bruce Ruggeri; Susan Jones-Bolin; Samuel R Denmeade; Douglas W Ball; Barry D Nelkin
Journal:  Cancer Res       Date:  2003-09-01       Impact factor: 12.701

3.  BRAF mutations typical of papillary thyroid carcinoma are more frequently detected in undifferentiated than in insular and insular-like poorly differentiated carcinomas.

Authors:  Paula Soares; Vítor Trovisco; Ana Sofia Rocha; Tália Feijão; Ana Paula Rebocho; Elsa Fonseca; Inês Vieira de Castro; José Cameselle-Teijeiro; Manuel Cardoso-Oliveira; Manuel Sobrinho-Simões
Journal:  Virchows Arch       Date:  2004-04-17       Impact factor: 4.064

4.  Prevalence of RET/PTC rearrangements in thyroid papillary carcinomas: effects of the detection methods and genetic heterogeneity.

Authors:  Zhaowen Zhu; Raffaele Ciampi; Marina N Nikiforova; Manoj Gandhi; Yuri E Nikiforov
Journal:  J Clin Endocrinol Metab       Date:  2006-06-13       Impact factor: 5.958

5.  Ret oncogene activation in human thyroid neoplasms is restricted to the papillary cancer subtype.

Authors:  M Santoro; F Carlomagno; I D Hay; M A Herrmann; M Grieco; R Melillo; M A Pierotti; I Bongarzone; G Della Porta; N Berger
Journal:  J Clin Invest       Date:  1992-05       Impact factor: 14.808

6.  Genetic alterations and their relationship in the phosphatidylinositol 3-kinase/Akt pathway in thyroid cancer.

Authors:  Peng Hou; Dingxie Liu; Yuan Shan; Shuiying Hu; Kimberley Studeman; Stephen Condouris; Yangang Wang; Ariel Trink; Adel K El-Naggar; Giovanni Tallini; Vasily Vasko; Mingzhao Xing
Journal:  Clin Cancer Res       Date:  2007-02-15       Impact factor: 12.531

7.  PAX8-PPARgamma rearrangement in thyroid tumors: RT-PCR and immunohistochemical analyses.

Authors:  Marina N Nikiforova; Paul W Biddinger; Christy M Caudill; Todd G Kroll; Yuri E Nikiforov
Journal:  Am J Surg Pathol       Date:  2002-08       Impact factor: 6.394

8.  High prevalence of RET rearrangement in thyroid tumors of children from Belarus after the Chernobyl reactor accident.

Authors:  S Klugbauer; E Lengfelder; E P Demidchik; H M Rabes
Journal:  Oncogene       Date:  1995-12-21       Impact factor: 9.867

9.  Activating point mutations of the gsp oncogene in human thyroid adenomas.

Authors:  C O'Sullivan; C M Barton; S L Staddon; C L Brown; N R Lemoine
Journal:  Mol Carcinog       Date:  1991       Impact factor: 4.784

Review 10.  RET/PTC rearrangement in thyroid tumors.

Authors:  Yuri E Nikiforov
Journal:  Endocr Pathol       Date:  2002       Impact factor: 3.943

View more
  9 in total

1.  Insulin glargine and insulin have identical effects on proliferation and phosphatidylinositol 3-kinase/AKT signalling in rat thyrocytes and human follicular thyroid cancer cells.

Authors:  K Müller; C Weidinger; D Führer
Journal:  Diabetologia       Date:  2010-02-24       Impact factor: 10.122

Review 2.  Genetic alterations in the phosphatidylinositol-3 kinase/Akt pathway in thyroid cancer.

Authors:  Mingzhao Xing
Journal:  Thyroid       Date:  2010-07       Impact factor: 6.568

3.  IQGAP1 plays an important role in the invasiveness of thyroid cancer.

Authors:  Zhi Liu; Dingxie Liu; Ermal Bojdani; Adel K El-Naggar; Vasily Vasko; Mingzhao Xing
Journal:  Clin Cancer Res       Date:  2010-10-19       Impact factor: 12.531

4.  Synergistic effect of metformin and vemurufenib (PLX4032) as a molecular targeted therapy in anaplastic thyroid cancer: an in vitro study.

Authors:  Latha Durai; Soundharya Ravindran; Krishnamurthy Arvind; Devarajan Karunagaran; Ramshankar Vijayalakshmi
Journal:  Mol Biol Rep       Date:  2021-10-30       Impact factor: 2.316

5.  Differentiated thyroid cancer in navarra (Spain): historic cohort results (1987-2003).

Authors:  María Pilar Salvador Egea; Ana Aranzazu Echegoyen Silanes; Eduardo Layana Echezuri; Emma Anda Apiñariz; Ana Puras Gil; Edelmiro Menéndez Torre; Lluis Forga Llenas; Amaya Sainz de Los Terreros
Journal:  ISRN Oncol       Date:  2011-07-31

6.  Role of the wnt pathway in thyroid cancer.

Authors:  Ana Sastre-Perona; Pilar Santisteban
Journal:  Front Endocrinol (Lausanne)       Date:  2012-02-29       Impact factor: 5.555

Review 7.  Immune response in thyroid cancer: widening the boundaries.

Authors:  Laura Sterian Ward
Journal:  Scientifica (Cairo)       Date:  2014-09-25

8.  β-catenin signaling is required for RAS-driven thyroid cancer through PI3K activation.

Authors:  Ana Sastre-Perona; Garcilaso Riesco-Eizaguirre; Miguel A Zaballos; Pilar Santisteban
Journal:  Oncotarget       Date:  2016-08-02

9.  Downregulation of miR‑193a‑3p via targeting cyclin D1 in thyroid cancer.

Authors:  Xiao-Jiao Li; Rong Wen; Dong-Yue Wen; Peng Lin; Deng-Hua Pan; Li-Jie Zhang; Yu He; Lin Shi; Yong-Ying Qin; Yun-Hui Lai; Jing-Ni Lai; Jun-Lin Yang; Qin-Qiao Lai; Jun Wang; Jun Ma; Hong Yang; Yu-Yan Pang
Journal:  Mol Med Rep       Date:  2020-07-08       Impact factor: 2.952

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.